MAPT and Atrophy: The blood-based brain-derived tau (BD-tau) has been used as a biomarker for identifying Aβ-positive individuals at risk of short-term cognitive decline and atrophy, with implications for clinical trials and implementation of anti-Aβ therapies [566].